Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical reported a pivotal second quarter of FY26, delivering record dose sales, with unit volumes up 60% and revenue rising 70% year-on-year, underscoring accelerating clinical adoption and strengthening market presence. The company completed its first commercial OncoSil™ treatments in Portugal, Germany and the UK, advanced European rollout with a successful production run at its new Sydney facility, received a $1.8 million R&D tax incentive to support ongoing development, reported encouraging real-world survival data from its OSPREY registry analysis, and announced the retirement of Non-Executive Director and former Chair Douglas Cubbin, collectively reinforcing its operational momentum and manufacturing capability in the pancreatic cancer treatment market.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is an Australian medical device company specialising in localised, intratumoural radiation therapies for patients with unresectable locally advanced pancreatic cancer. The company’s lead product, the OncoSil™ device, is a targeted radiotherapy implant designed to be used alongside chemotherapy, with a growing commercial focus on major European healthcare markets including Portugal, Germany and the UK.
Average Trading Volume: 24,984
Technical Sentiment Signal: Sell
Current Market Cap: A$15.87M
For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.